Weekly Digest – August 2026 Weekly Digest – August 2026 31 July 2026: Datroway approved in the EU for first-line metastatic TNBC patients unsuitable for immunotherapy Daiichi Sankyo and AstraZeneca announced that Datroway has been approved in the EU as […]
Weekly Digest – August 2026 Weekly Digest – August 2026 31 July 2026: FDA approves Pluvicto for PSMA+ mHSPC, advancing potential new standard of care across metastatic disease Novartis announced that the U.S. FDA has approved Pluvicto in combination with […]
Weekly Digest – July 2026 Weekly Digest – July 2026 28 July 2026: AstraZeneca receives CDSCO approval for Enhertu followed by THP for adults with HER2-positive stage II or III early Breast cancer AstraZeneca Pharma India announced that the Central […]
Weekly Digest – July 2026 Weekly Digest – July 2026 29 July 2026: ImmunityBio receives UAE Marketing Authorization for ANKTIVA in BCG-unresponsive NMIBC (CIS and papillary disease) and mNSCLC ImmunityBio announced that the United Arab Emirates has granted marketing authorization […]
Weekly Digest – July 2026 Weekly Digest – July 2026 17 July 2026: Biokin Pharma announces approval of Iza-bren in China for the treatment of recurrent/metastatic ESCC Biokin Pharma announced that China’s NMPA has approved Iza-bren for the treatment of […]
Weekly Digest – July 2026 Weekly Digest – July 2026 10 July 2026: U.S. FDA approves PADCEV plus Keytruda as neoadjuvant and adjuvant treatment for MIBC regardless of cisplatin eligibility The U.S. FDA has approved PADCEV plus KEYTRUDA as neoadjuvant […]
